istock-629794242xesai-1

Xesai / iStockphoto.com

7 June 2018Big Pharma

GSK completes buyout of Novartis from joint venture

GSK has confirmed that its $13 billion buyout of Novartis from the companies’ consumer healthcare joint venture has been completed following approval from shareholders.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

GSK and Pfizer sign joint venture, but will demerge after three years

20 December 2018 Pharmaceutical companies GSK and Pfizer yesterday announced that they will combine their consumer health businesses into a new joint venture with sales of approximately £9.8 billion ($12.7 billion).

GSK seeks to boost oncology repertoire with $5.1bn acquisition

3 December 2018 GSK has agreed to buy US oncology company Tesaro for $5.1 billion, in a move designed to strengthen its anti-cancer offering.

GSK buys out Novartis in $13bn consumer healthcare deal

27 March 2018 GSK has revealed that it will buy Novartis out of their joint consumer healthcare business.

More on this story

GSK and Pfizer sign joint venture, but will demerge after three years

20 December 2018 Pharmaceutical companies GSK and Pfizer yesterday announced that they will combine their consumer health businesses into a new joint venture with sales of approximately £9.8 billion ($12.7 billion).

GSK seeks to boost oncology repertoire with $5.1bn acquisition

3 December 2018 GSK has agreed to buy US oncology company Tesaro for $5.1 billion, in a move designed to strengthen its anti-cancer offering.

GSK buys out Novartis in $13bn consumer healthcare deal

27 March 2018 GSK has revealed that it will buy Novartis out of their joint consumer healthcare business.

More on this story

GSK and Pfizer sign joint venture, but will demerge after three years

20 December 2018 Pharmaceutical companies GSK and Pfizer yesterday announced that they will combine their consumer health businesses into a new joint venture with sales of approximately £9.8 billion ($12.7 billion).

GSK seeks to boost oncology repertoire with $5.1bn acquisition

3 December 2018 GSK has agreed to buy US oncology company Tesaro for $5.1 billion, in a move designed to strengthen its anti-cancer offering.

GSK buys out Novartis in $13bn consumer healthcare deal

27 March 2018 GSK has revealed that it will buy Novartis out of their joint consumer healthcare business.

More features

Patent attorneys by day, coders by night: Sterne Kessler launches ‘homemade’ AI assistant

Mental health IP toolkit: Diversity Champ’s stress-busting tips

Eli Lilly piles on weight loss drug suits to ward off revenue squeeze

Patent cliff: 5 blockbusters running out of road

Herbert Smith Freehills expands German tech patent team

‘Always new twists’: Bayer legal team on defending a $4bn drug

Novartis and MSN feud intensifies after Fed Circ denies rehearing

EU court signals tough stance on ‘pay-for-delay’ pharma deals